脂肪营养不良 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-30 and is reviewed periodically as new material appears.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
== External links == "Real-world Evidence from a Narrow Therapeutic Index Product (Levothyroxine) Reflects the Therapeutic Equivalence of Generic Drug Products". U.S. Food and Drug Administration (FDA). 19 November 2020. Archived from the original on 2 October 2020. Levothyroxine pronunciation guide – audio, phonetic spelling, and syllable breakdown
=== Views on homosexuality === Jung addressed homosexuality in his published writings, in one comment specifying that homosexuality should not be a concern of legal authorities nor be considered a crime. He also stated that homosexuality does not reduce the value of a person as a member of society. Jung also said that homosexuality is a result of psychological immaturity ("nurture"), but only if one's sexuality is not an aspect of their constitutional characteristics ("nature").
The chromerids are a group of algae known from Australian corals which comprise some close photosynthetic relatives of the apicomplexans. The first member, Chromera velia, was discovered and first isolated in 2001. The discovery of Chromera velia with similar structure to the apicomplexans, provides an important link in the evolutionary history of the apicomplexans and dinophytes. Their plastids have four membranes, lack chlorophyll c and use the type II form of RuBisCO obtained from a horizontal transfer event.
=== Romanian Revolution === List of books about the Romanian Revolution List of films about the Romanian Revolution Ilie Verdeț, tried to take over power on 22 Dec 1989, but was pushed aside by I. Iliescu Videograms of a Revolution
The glucose content of the blood is regulated by the hormones insulin, incretin, and glucagon. Insulin lowers the glucose level, glucagon increases it. Furthermore, the hormones adrenaline, thyroxine, glucocorticoids, somatotropin, and adrenocorticotropin lead to an increase in the glucose level. There is also a hormone-independent regulation, which is referred to as glucose autoregulation. After food intake the blood sugar concentration increases. Values over 180 mg/dL in venous whole blood are pathological and are termed hyperglycemia, values below 40 mg/dL are termed hypoglycaemia. When needed, glucose is released into the bloodstream by glucose-6-phosphatase from glucose-6-phosphate originating from liver and kidney glycogen, thereby regulating the homeostasis of blood glucose concentration. In ruminants, the blood glucose concentration is lower (60 mg/dL in cattle and 40 mg/dL in sheep), because the carbohydrates are converted more by their gut microbiota into short-chain fatty acids. Some glucose is converted to lactic acid by astrocytes, which is then used as an energy source by brain cells; some glucose is used by intestinal cells and red blood cells, while the rest reaches the liver, adipose tissue, and muscle cells, where it is absorbed and stored as glycogen (under the influence of insulin). Liver cell glycogen can be converted to glucose and returned to the blood when insulin is low or absent; muscle cell glycogen is not returned to the blood because of a lack of enzymes.
Sources: en.wikipedia.org
=== Logo === The design was created by McLean Design, a California-based strategic branding firm. The logo is composed of a vibrant green "M", composed of three lines on a field of black. The "M" is stylized in such a way as to imply that it is formed by the claws of a monster ripping through the can.
=== Sultanate and Kingdom of Egypt (1915–1953) === Brigadier Peter Acland (4th class), 1936 Sir Pratap Singh of Idar (Grand Cordon), 1918 Judge Sir Maurice Amos (Grand Cordon) Maharaja Jagatjit Singh Bahadur of Kapurthala (Grand Cordon), 1924 Major Henry Beaumont (4th Class), 1916 Rear Admiral Richard Bevan (4th Class), 1919 Field Marshall Lord Birdwood Lieutenant General Louis Bols Lieutenant Colonel Arthur Borton VC, DSO (3rd Class) Howard Carter, British archaeologist and Egyptologist (3rd Class), 1926 Jovan Dučić Major Aubrey Faulkner Major General Harold Franklyn, Commandant Sudan Defence Force, 1939 Major Harry Gardner (4th Class), 1922 Lieutenant Colonel Alexander Kearsey (3rd Class) Harold Knox-Shaw, British astronomer Lancelot Lowther, 6th Earl of Lonsdale, 1920 Naguib Pasha Mahfouz, obstetrician and gynecologist, 1919 Lieutenant Colonel Cecil L'Estrange Malone David McAllister, Engineer-in-Chief, Egyptian State Railways, (3rd Class), 1916 Earl Mountbatten of Burma, (fourth class), 1922 Charles Paget, 6th Marquess of Anglesey, 1915 General Sir William Peyton (2nd Class), 1916 General Hussein Refki Pasha (Grand Cordon) Admiral of the Fleet The Earl of Cork and Orerry, 3rd class (1916) Admiral Francis Mitchell (Royal Navy officer) Rear Admiral Eric Gascoigne Robinson Captain George Francis Scott Elliot Dr. Hassan Omar Shaheen – Professor of ENT Kasr El-Aini Hospital, Cairo. Circa 1920 Major-General Sir Charlton Watson Spinks, last Sirdar of Egypt (Grand Cordon), 1931 Dr.
Amylases break down the polysaccharides in flour into smaller sugars, thereby feeding the yeast cells. (Malted barley is a good natural source of amylase enzymes) Proteases (e.g papain) improve extensibility of the dough by degrading some of the gluten. Lipoxygenases oxidize components within the flour.
Most of these biological functions are affected by the isomerization of proline when one isomer interacts differently than the other, commonly causing an activation/deactivation relationship. As an amino acid, proline is present in many proteins. This aids in the multitude of effects that isomerization of proline can have in different biological mechanisms and functions.
Sources: en.wikipedia.org
Robert H. Christenson, PhD, DABCC, FACB, is the current President of the American Association for Clinical Chemistry, AACC. As of 2026, he is a professor of pathology and professor of medical and research technology at the University of Maryland School of Medicine in Baltimore. He is a member of the editorial boards of Clinical Chemistry and the Journal of Clinical and Laboratory Analysis, and associate editor of Clinical Biochemistry.
== Nomenclature == Accepted nomenclature is to designate the number of components of the rotaxane in brackets as a prefix. Therefore, the rotaxane consisting of a single dumbbell-shaped axial molecule with a single macrocycle around its shaft is called a [2]rotaxane, and two cyanostar molecules around the central phosphate group of dialkylphosphate is a [3]rotaxane.
== Uses in cell biology == Verapamil inhibits the ATP-binding cassette (ABC) transporter family of proteins found in stem cells and has been used to study cancer stem cells (CSC) within head and neck squamous cell carcinomas. Verapamil is also used in cell biology as an inhibitor of drug efflux pump proteins such as P-glycoprotein and other ABC transporter proteins. This is useful, as many tumor cell lines overexpress drug efflux pumps, limiting the effectiveness of cytotoxic drugs or fluorescent tags. It is also used in fluorescent cell sorting for DNA content, as it blocks efflux of a variety of DNA-binding fluorophores such as Hoechst 33342. Radioactively labelled verapamil and positron emission tomography can be used with to measure P-glycoprotein function.
=== Analogues === Although several related compounds are disclosed in the original patent, no activity data are provided and it was unclear whether these share tianeptine's unique pharmacological effects. More recent structure-activity relationship studies have since been conducted, providing some further insight on μ-opioid, δ-opioid, and pharmacokinetic activity. Derivatives where the aromatic chlorine substituent is replaced by bromine, iodine or methylthio, and/or the heptanoic acid tail is varied in length or replaced with other groups such as 3-methoxypropyl, show similar or increased opioid receptor activity relative to tianeptine, with up to 13x higher potency than tianeptine itself. Amineptine, the most closely related drug to have been widely studied, is a dopamine reuptake inhibitor with no significant effect on serotonin levels, nor opioid agonist activity. Tianeptinaline and tianeptinostat, analogues of tianeptine, are potent histone deacetylase (HDAC) inhibitors.
By July 2019, this has not happened, according to The Record. Critics raised concerns that Hydro One will not experience stability as Premier Ford's government has a "record of reaching in to exert control." On March 21, 2019, Minister Rickford tabled Bill 87, the Fixing the Hydro Mess Act, which was given royal assent on May 9. Bill 87 overhauled the Ontario Energy Board and eliminated the Liberal's 2017 Fair Hydro Plan which the PC's said would save $442 million. The Liberal Plan "subsidized electricity with borrowed money" in response to a "public outcry over soaring hydro rates, particularly in rural areas." The Liberals created the Ontario Power Generation Inc (OPG Trust) as the Financial Services Manager to manage the debt. Bonnie Lysyk, the Auditor General, released a special report on October 17, 2017, which said the "structure of the plan" was in violation of the provincial government's accounting rules. She said that the Plan, which committed the government to discount consumer electricity rates for ten years, would cost the province "$21 billion in interest over the next 30 years." The 2017 AG report said that it would cost $4 billion more on the $18.4 billion loan to use the Ontario Power Generation (OPG Trust) than if the province took out the loan because the province would have a lower interest rate than the OPG Trust. The Ford government said that they would maintain [the] 25 per cent time-of-use rates, that was part of the Liberal's Fair Hydro Plan.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.